Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript

Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia February 3, 2026 10:30 ...
CNN

Minerva Neurosciences to Host Key Opinion Leader Meeting on Avolition, the Most Central Domain for the Successful Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat ...